Loading organizations...
§ Private Profile · 3rd Floor, AIC-CCMB, New Nagole Colony, Nagendra Nagar, Uppal, Hyderabad, Telangana 500007, India
Molecular diagnostics company developing D-LAMP technology for rapid, room-temperature detection of pathogens and antimicrobial resistance.
Based in Gurugram, Haryana, India, D-Nome is a deep-tech biotechnology startup that develops molecular diagnostic tools for the rapid detection of pathogen-borne diseases and antimicrobial resistance at room temperature. The company utilizes its patented D-LAMP platform technology, which relies on synthetic biology to provide scalable alternatives to traditional RT-PCR testing without requiring complex machinery or temperature-controlled environments. Operating under a One Health thesis, the enterprise targets the healthcare, life sciences, and agricultural sectors, conducting pilot programs for livestock screening with commercial clients such as Sh NASA Farms. The firm has raised $1.5 million in total funding from investors including 3i Partners and previously won the medical category of the Hello Tomorrow challenge against over 4,000 global applicants, alongside industry prizes sponsored by Syngene and Cytiva. D-Nome was founded in 2021 by Divya Sriram and Sujoy Deb.
D-Nome has raised $2.0M across 1 funding round.
D-Nome has raised $2.0M in total across 1 funding round.
D-Nome has raised $2.0M in total across 1 funding round.
D-Nome's investors include Ankur Capital, Shalini Chhabra, 8X Ventures, Campus Fund, Seeders.
D-Nome has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in January 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 1, 2023 | $2M Seed | Ankur Capital | Shalini Chhabra, 8X Ventures, Campus Fund, Seeders | Announced |
D-Nome is a health-tech startup founded in 2021 and based in Hyderabad, India, specializing in cell-free synthetic biology for rapid, accurate, and scalable molecular diagnostics.[1][2][3] It develops the proprietary D-LAMP platform—an enzyme mix enabling nucleic acid amplification at room temperature (37°C) without specialized equipment—targeting healthcare providers, diagnostic kit manufacturers, and research institutions facing limitations in traditional methods like complexity, time, and infrastructure needs.[2][3][4][5] The company has raised approximately $1.5M from investors including Entrepreneur First, Ankur Capital, Campus Fund, Rebalance, and Impact India Investment Partners, with a small team of 6 employees driving growth in democratizing genomics-based testing.[2][6]
This SaaS-enabled solution addresses critical gaps in diagnostic data management and analysis, particularly in resource-limited settings, by simplifying processes and reducing reliance on labs and skilled personnel.[1][2][5]
D-Nome emerged in 2021 from Hyderabad, Telangana, India, as a deep-tech venture at the AIC-CCMB incubator (3rd Floor, AIC-CCMB, Uppal), founded by a team backed early by Entrepreneur First.[2][3][4] The idea stemmed from recognizing flaws in conventional molecular diagnostics—such as slow speed, inaccuracy, and scalability issues in resource-constrained environments—prompting the creation of cell-free synthetic biology tools like D-LAMP for "deviceless" testing.[2][5] Early traction came via portfolio inclusion in Entrepreneur First's network and seed funding totaling $1.5M, fueling development of platform applications beyond diagnostics.[2][3][6] Pivotal moments include refining D-LAMP for room-temperature use, positioning it as a next-generation alternative to PCR sequencing diagnostics.[4][5][6]
D-Nome rides the global surge in synthetic biology and point-of-care diagnostics, accelerated by pandemics highlighting needs for fast, decentralized testing amid rising chronic diseases and antimicrobial resistance.[2][3] Timing aligns with India's health-tech boom—fueled by government initiatives like AIC incubators and investor focus on deep-tech—and falling genomics costs, making scalable solutions viable.[1][3][6] Market forces like resource-limited healthcare in emerging economies favor its deviceless model, influencing the ecosystem by enabling affordable genomics for startups, labs, and global health equity.[2][5]
D-Nome's momentum—$1.5M funding, D-LAMP refinements, and EF backing—positions it for partnerships with diagnostic manufacturers and expansion into sequencing or multi-disease kits.[2][4][6] Trends like AI-integrated synth-bio and decentralized health (e.g., wearables, at-home tests) will shape its path, potentially scaling to 10x growth via international pilots. Its influence may evolve from niche innovator to ecosystem enabler, amplifying accessible diagnostics as synth-bio matures, tying back to its core mission of decoding genomics efficiently.[3][5]